Delcath Systems Innovates Liver Cancer Treatment with HEPZATO KIT™ Breakthrough

Delcath Systems Advances Cancer Treatment with HEPZATO KIT™

Delcath Systems, Inc., a Queensbury-based interventional oncology company, is making significant strides in the treatment of primary and metastatic liver cancers through its innovative products, particularly the HEPZATO KIT™. This FDA-approved combination of melphalan and the Hepatic Delivery System (HDS) provides a targeted approach to chemotherapy, delivering high doses directly to the liver while minimizing systemic exposure and side effects. This method enhances the potential for substantial tumor responses while reducing the risk of hepatotoxicity, making it a crucial advancement in the fight against liver cancer.

The HEPZATO KIT is specifically approved for adult patients in the United States suffering from metastatic uveal melanoma (mUM) and unresectable hepatic metastases, under strict conditions where less than half of the liver is affected. This targeted treatment options positions Delcath Systems at the forefront of interventional oncology, addressing a significant unmet need for effective therapies in liver cancer, which often presents with limited treatment options. By isolating hepatic venous blood from systemic circulation during the infusion and washout process, the HEPZATO KIT ensures that high concentrations of melphalan can be delivered locally, thus maximizing efficacy while maintaining patient safety.

On the global stage, the CHEMOSAT® Hepatic Delivery System, recognized as a Class III medical device in Europe, has already demonstrated effectiveness across major medical centers for various liver cancer treatments. This recognition underscores the growing acceptance and integration of Delcath's technologies within the oncology community, further solidifying the company’s position as a leader in hepatocellular carcinoma and other liver-related cancers. As Delcath Systems prepares to showcase its innovations at the upcoming BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in February 2025, it remains committed to advancing interventional oncology and improving treatment outcomes for patients facing challenging cancer diagnoses.

In addition to its proprietary products, Delcath Systems focuses on educating healthcare professionals about the benefits and applications of its technologies. The company emphasizes the importance of understanding potential risks associated with the HEPZATO KIT, including those outlined in the BOXED WARNING. This commitment to transparency ensures that clinicians are well-informed when considering treatment options for their patients.

As Delcath continues to innovate and expand its presence in the oncology field, its advancements in liver cancer treatment signal a promising future for patients and healthcare providers alike. By prioritizing local delivery systems, Delcath Systems not only enhances therapeutic efficacy but also contributes to the overall improvement of patient care in oncology.